{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.8","upperLimit":"49.7","value":"42.6"},{"groupId":"OG001","lowerLimit":"21.5","upperLimit":"34.1","value":"27.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"title":"BASELINE PD-L1 EXPRESSION ≥1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.4","upperLimit":"39.6","value":"31.1"},{"groupId":"OG001","lowerLimit":"13.6","upperLimit":"28.1","value":"20.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"129"}],"units":"Participants"}],"title":"BASELINE PD-L1 EXPRESSION < 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.2","upperLimit":"59.3","value":"36.4"},{"groupId":"OG001","lowerLimit":"14.9","upperLimit":"53.5","value":"32.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Non-Quantifiable PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.8","upperLimit":"47.3","value":"38.3"},{"groupId":"OG001","lowerLimit":"15.9","upperLimit":"32.8","value":"23.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"BASELINE PD-L1 EXPRESSION 1 - 49%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.3","upperLimit":"61.7","value":"50.0"},{"groupId":"OG001","lowerLimit":"22.6","upperLimit":"41.8","value":"31.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"BASELINE PD-L1 EXPRESSION >= 50%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"description":"ORR was defined as the proportion of randomized participants with a best overall response (BOR) of confirmed complete or partial response per BICR using RECIST v1.1. BOR was assessed from randomization until documented progression, start of palliative local or subsequent anti-cancer therapy-whichever came first. If none occurred, all response data contributed to BOR. For those treated beyond progression, BOR was based on responses before initial RECIST-defined progression. PD-L1 expression was measured via Dako PD-L1 IHC 28-8 pharmDx test as the percentage of tumor cells with membrane staining among ≥100 evaluable cells. Expression was categorized as ≥1%, \\<1%, not quantifiable, ≥50%, or 1-49%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Ipilimumab + Chemotherapy","id":"OG000","title":"Treatment A"},{"description":"Chemotherapy only","id":"OG001","title":"Treatment B"}],"paramType":"NUMBER","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","title":"Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}